Pharmacokinetic Characteristics of 5‐Fluorouracil and Mitomycin C in Intraperitoneal Chemotherapy

TAKAFUMI KUZUYA, MASAJI YAMAUCHI, AKIHIRO ITO, MASAYA HASEGAWA, TAKAAKI HASEGAWA, TOSHITAKA NABESHIMA

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Abstract— Eight patients with malignancies confined to the peritoneal space participated in this study. Five hundred milligrams 5‐fluorouracil or 10 mg mitomycin C was diluted in 1 L saline. The mixed solution was injected intraperitoneally through the semi‐permanent peritoneal catheter. Blood and peritoneal fluid were collected after injection. 5‐Fluorouracil concentrations in the peritoneal fluid were 1000 times those in serum, while mitomycin C concentrations were 100 times those in serum. Areas under the concentration vs time curve (AUC) were calculated by the trapezoidal method with extrapolation to infinity. The ratio of peritoneal fluid AUC to serum AUC was about 1400 for 5‐fluorouracil and 80 for mitomycin C. Patterns for the absorption and elimination from systemic circulation were similar for both compounds. Drug concentrations in the peritoneal fluid and serum were analysed according to the compartment model. The half‐life in the peritoneal fluid (t½p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5‐fluorouracil and mitomycin C (t½p, 1·0 h for 5‐fluorouracil and 1·3 h for mitomycin C; ka 0·71 h−1 for 5‐fluorouracil and 0·68 h−1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 Lm−2 and 1.8 L h−1 m−2) were about twice the values for 5‐fluorouracil (149 L m−2 and 0·8 L h−1 m−2). 1994 Royal Pharmaceutical Society of Great Britain

Original languageEnglish
Pages (from-to)685-689
Number of pages5
JournalJournal of Pharmacy and Pharmacology
Volume46
Issue number8
DOIs
Publication statusPublished - 01-01-1994
Externally publishedYes

Fingerprint

Mitomycin
Ascitic Fluid
Pharmacokinetics
Drug Therapy
Area Under Curve
Serum
Peritoneal Cavity
Half-Life
Catheters
Injections
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

KUZUYA, TAKAFUMI ; YAMAUCHI, MASAJI ; ITO, AKIHIRO ; HASEGAWA, MASAYA ; HASEGAWA, TAKAAKI ; NABESHIMA, TOSHITAKA. / Pharmacokinetic Characteristics of 5‐Fluorouracil and Mitomycin C in Intraperitoneal Chemotherapy. In: Journal of Pharmacy and Pharmacology. 1994 ; Vol. 46, No. 8. pp. 685-689.
@article{dd8d71f75d0741829795ebad713982b6,
title = "Pharmacokinetic Characteristics of 5‐Fluorouracil and Mitomycin C in Intraperitoneal Chemotherapy",
abstract = "Abstract— Eight patients with malignancies confined to the peritoneal space participated in this study. Five hundred milligrams 5‐fluorouracil or 10 mg mitomycin C was diluted in 1 L saline. The mixed solution was injected intraperitoneally through the semi‐permanent peritoneal catheter. Blood and peritoneal fluid were collected after injection. 5‐Fluorouracil concentrations in the peritoneal fluid were 1000 times those in serum, while mitomycin C concentrations were 100 times those in serum. Areas under the concentration vs time curve (AUC) were calculated by the trapezoidal method with extrapolation to infinity. The ratio of peritoneal fluid AUC to serum AUC was about 1400 for 5‐fluorouracil and 80 for mitomycin C. Patterns for the absorption and elimination from systemic circulation were similar for both compounds. Drug concentrations in the peritoneal fluid and serum were analysed according to the compartment model. The half‐life in the peritoneal fluid (t½p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5‐fluorouracil and mitomycin C (t½p, 1·0 h for 5‐fluorouracil and 1·3 h for mitomycin C; ka 0·71 h−1 for 5‐fluorouracil and 0·68 h−1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 Lm−2 and 1.8 L h−1 m−2) were about twice the values for 5‐fluorouracil (149 L m−2 and 0·8 L h−1 m−2). 1994 Royal Pharmaceutical Society of Great Britain",
author = "TAKAFUMI KUZUYA and MASAJI YAMAUCHI and AKIHIRO ITO and MASAYA HASEGAWA and TAKAAKI HASEGAWA and TOSHITAKA NABESHIMA",
year = "1994",
month = "1",
day = "1",
doi = "10.1111/j.2042-7158.1994.tb03883.x",
language = "English",
volume = "46",
pages = "685--689",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "8",

}

Pharmacokinetic Characteristics of 5‐Fluorouracil and Mitomycin C in Intraperitoneal Chemotherapy. / KUZUYA, TAKAFUMI; YAMAUCHI, MASAJI; ITO, AKIHIRO; HASEGAWA, MASAYA; HASEGAWA, TAKAAKI; NABESHIMA, TOSHITAKA.

In: Journal of Pharmacy and Pharmacology, Vol. 46, No. 8, 01.01.1994, p. 685-689.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetic Characteristics of 5‐Fluorouracil and Mitomycin C in Intraperitoneal Chemotherapy

AU - KUZUYA, TAKAFUMI

AU - YAMAUCHI, MASAJI

AU - ITO, AKIHIRO

AU - HASEGAWA, MASAYA

AU - HASEGAWA, TAKAAKI

AU - NABESHIMA, TOSHITAKA

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Abstract— Eight patients with malignancies confined to the peritoneal space participated in this study. Five hundred milligrams 5‐fluorouracil or 10 mg mitomycin C was diluted in 1 L saline. The mixed solution was injected intraperitoneally through the semi‐permanent peritoneal catheter. Blood and peritoneal fluid were collected after injection. 5‐Fluorouracil concentrations in the peritoneal fluid were 1000 times those in serum, while mitomycin C concentrations were 100 times those in serum. Areas under the concentration vs time curve (AUC) were calculated by the trapezoidal method with extrapolation to infinity. The ratio of peritoneal fluid AUC to serum AUC was about 1400 for 5‐fluorouracil and 80 for mitomycin C. Patterns for the absorption and elimination from systemic circulation were similar for both compounds. Drug concentrations in the peritoneal fluid and serum were analysed according to the compartment model. The half‐life in the peritoneal fluid (t½p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5‐fluorouracil and mitomycin C (t½p, 1·0 h for 5‐fluorouracil and 1·3 h for mitomycin C; ka 0·71 h−1 for 5‐fluorouracil and 0·68 h−1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 Lm−2 and 1.8 L h−1 m−2) were about twice the values for 5‐fluorouracil (149 L m−2 and 0·8 L h−1 m−2). 1994 Royal Pharmaceutical Society of Great Britain

AB - Abstract— Eight patients with malignancies confined to the peritoneal space participated in this study. Five hundred milligrams 5‐fluorouracil or 10 mg mitomycin C was diluted in 1 L saline. The mixed solution was injected intraperitoneally through the semi‐permanent peritoneal catheter. Blood and peritoneal fluid were collected after injection. 5‐Fluorouracil concentrations in the peritoneal fluid were 1000 times those in serum, while mitomycin C concentrations were 100 times those in serum. Areas under the concentration vs time curve (AUC) were calculated by the trapezoidal method with extrapolation to infinity. The ratio of peritoneal fluid AUC to serum AUC was about 1400 for 5‐fluorouracil and 80 for mitomycin C. Patterns for the absorption and elimination from systemic circulation were similar for both compounds. Drug concentrations in the peritoneal fluid and serum were analysed according to the compartment model. The half‐life in the peritoneal fluid (t½p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5‐fluorouracil and mitomycin C (t½p, 1·0 h for 5‐fluorouracil and 1·3 h for mitomycin C; ka 0·71 h−1 for 5‐fluorouracil and 0·68 h−1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 Lm−2 and 1.8 L h−1 m−2) were about twice the values for 5‐fluorouracil (149 L m−2 and 0·8 L h−1 m−2). 1994 Royal Pharmaceutical Society of Great Britain

UR - http://www.scopus.com/inward/record.url?scp=0028170173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028170173&partnerID=8YFLogxK

U2 - 10.1111/j.2042-7158.1994.tb03883.x

DO - 10.1111/j.2042-7158.1994.tb03883.x

M3 - Article

C2 - 7815285

AN - SCOPUS:0028170173

VL - 46

SP - 685

EP - 689

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 8

ER -